These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26055179)

  • 1. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.
    Vallo S; Michaelis M; Rothweiler F; Bartsch G; Gust KM; Limbart DM; Rödel F; Wezel F; Haferkamp A; Cinatl J
    Transl Oncol; 2015 Jun; 8(3):210-6. PubMed ID: 26055179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.
    Vallo S; Köpp R; Michaelis M; Rothweiler F; Bartsch G; Brandt MP; Gust KM; Wezel F; Blaheta RA; Haferkamp A; Cinatl J
    Oncol Lett; 2017 Jun; 13(6):4085-4092. PubMed ID: 28599410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
    Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
    Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
    Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.
    Vallo S; Rutz J; Kautsch M; Winkelmann R; Michaelis M; Wezel F; Bartsch G; Haferkamp A; Rothweiler F; Blaheta RA; Cinatl J
    Oncol Lett; 2017 Nov; 14(5):5513-5518. PubMed ID: 29113179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel.
    Kathawala RJ; Wang YJ; Shukla S; Zhang YK; Alqahtani S; Kaddoumi A; Ambudkar SV; Ashby CR; Chen ZS
    Chin J Cancer; 2015 Mar; 34(3):115-20. PubMed ID: 25962593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
    Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
    Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
    Vallo S; Michaelis M; Gust KM; Black PC; Rothweiler F; Kvasnicka HM; Blaheta RA; Brandt MP; Wezel F; Haferkamp A; Cinatl J
    BMC Res Notes; 2016 Sep; 9(1):454. PubMed ID: 27677700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.
    Morel A; Talbot D
    Open Access J Urol; 2010 Jun; 2():99-108. PubMed ID: 24198619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
    Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
    Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
    Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
    Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
    Oba T; Izumi H; Ito KI
    Oncotarget; 2016 Oct; 7(43):70011-70027. PubMed ID: 27588398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
    Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
    Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.
    Kimiya K; Naito S; Soejima T; Sakamoto N; Kotoh S; Kumazawa J; Tsuruo T
    J Urol; 1992 Aug; 148(2 Pt 1):441-5. PubMed ID: 1353119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.